Esperion Therapeutics - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsEsperion Therapeutics

Esperion Therapeutics(ESPR)

Esperion Therapeutics, Inc. is a public American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

*Currency in USD

Company Revenue

Quarterly

Quarterly

Annual

Annual

Projections

*Quarterly sales USD (in millions)

Plot placeholder

Mock data
Subscribe for the real data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Nexletol	Bempedoic acid	2020-02-21	2025-2040	Hypercholesterolemia , Dyslipidemias , Atherosclerosis , Hyperlipoproteinemia type ii , Familial combined hyperlipidemia
Nexlizet	Bempedoic acid, Ezetimibe	2020-02-26	2025-2040	Hypercholesterolemia , Dyslipidemias , Atherosclerosis , Hyperlipoproteinemia type ii , Familial combined hyperlipidemia

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

hypercholesterolemia

,

hyperlipidemias

,

,

familial combined hyperlipidemia

pharmacokinetics

,

drug interactions

,

immunosuppression therapy

,

,

pharmacological phenomena

,

,

therapeutic equivalency

,

endometrial neoplasms

,

acute kidney injury

,

alopecia areata

,

,

pancreatic ductal carcinoma

,

pancreatic neoplasms

,

,

healthy volunteers/patients

,

chronic hepatitis

,

chronic hepatitis d

,

,

prostatic neoplasms

,

diabetic neuropathies

,

polyneuropathies

,

oxidative stress

,

,

hyperlipoproteinemia type ii

,

homozygous familial hypercholesterolemia

,

inborn errors lipid metabolism

,

inborn errors metabolism

,

essential hypertension

,

vascular diseases

,

aortic valve stenosis

,

pathologic constriction

,

left ventricular hypertrophy

,

,

diabetic nephropathies

,

,

kidney transplantation

,

lung transplantation

,

communicable diseases

,

insulin resistance

,

,

hypercholesterolemia

,

,

coronary artery disease

,

hyperlipidemias

,

coronary disease

,

atherosclerosis

,

myocardial ischemia

,

cardiovascular diseases

,

,

diabetes mellitus

,

type 2 diabetes mellitus

,

hyperlipoproteinemias

,

acute coronary syndrome

,

,

myocardial infarction

,

,

metabolic syndrome

,

,

atherosclerotic plaque

,

,

,

,

hypertriglyceridemia

,

kidney diseases

,

,

peripheral arterial disease

,

chronic renal insufficiency

,

st elevation myocardial infarction

,

metabolic diseases

,

,

non-alcoholic fatty liver disease

,

,

familial combined hyperlipidemia

,

ischemic stroke

,

,

lipid metabolism disorders

,

drug-related side effects and adverse reactions

,

peripheral vascular diseases

,

chronic hepatitis c

,

,

,

type 1 diabetes mellitus

,

non-st elevated myocardial infarction

,

cognitive dysfunction

,

,

alcoholic fatty liver

,

carotid artery diseases

,

preconception care

,

renin-angiotensin system

,

vitamin d deficiency

,

endocrine system diseases

,

nutritional and metabolic diseases

,

left ventricular dysfunction

,

vascular stiffness

,

transplantation

,

renal insufficiency

,

atrial fibrillation

,

magnetic resonance imaging

,

neuropsychology

,

,

arteriosclerosis

,

chronic disease

,

vascular calcification

,

,

intracranial arteriosclerosis

,

inferior wall myocardial infarction

,

,

cerebrovascular disorders

,

prediabetic state

,

hyperlipoproteinemia type v

,

,

genetic testing

,

hyperlipoproteinemia type iii

,

,

medication adherence

,

treatment adherence and compliance

,

patient compliance

,

motivational interviewing

,

,

intestinal diseases

,

heart disease risk factors

,

glucose intolerance

,

,

acalculous cholecystitis

,

alzheimer disease

,

,

,

coronavirus infections

,

,

,

disease progression

,

thrombocytopenic purpura idiopathic

,

thrombocytopenia

,

cerebral infarction

,

secondary prevention

,

cerebral small vessel diseases

,

percutaneous coronary intervention

,

cardiomyopathies

healthy volunteers/patients

,

pharmacokinetics

,

biological availability

,

prostatic neoplasms

,

medical sociology

,

,

,

drug interactions

,

,

,

chronic kidney failure

,

therapeutic equivalency

,

,

non-small-cell lung carcinoma

,

ischemic stroke

,

replacement arthroplasty knee

,

,

,

bariatric surgery

,

transient ischemic attack

,

cerebral infarction

,

venous thrombosis

,

acute coronary syndrome

,

,

surgical blood loss

,

renal insufficiency

,

postoperative hemorrhage

,

,

,

,

rheumatic diseases

,

myocardial infarction

,

myocardial ischemia

,

kidney diseases

,

esophageal neoplasms

,

,

respiratory distress syndrome

,

coronavirus infections

,

severe acute respiratory syndrome

,

,

aortic valve stenosis

,

heart valve diseases

,

ventricular outflow obstruction

,

rheumatic heart disease

,

transcatheter aortic valve replacement

,

,

percutaneous coronary intervention

,

unstable angina

,

knee osteoarthritis

,

hip osteoarthritis

,

,

,

chronic renal insufficiency

,

,

respiratory insufficiency

,

communicable diseases

,

collagen diseases

,

coronary disease

,

,

thrombophlebitis

,

atrial fibrillation

,

thromboembolism

,

venous thromboembolism

,

,

,

pulmonary embolism

,

,

,

peripheral arterial disease

,

coronary artery disease

,

,

cardiovascular diseases

,

,

atherosclerosis

,

respiratory tract diseases

,

embolism and thrombosis

,

,

,

antiphospholipid syndrome

,

,

intermittent claudication

,

,

carotid stenosis

,

peripheral vascular diseases

,

atherosclerotic plaque

,

replacement arthroplasty hip

,

intracranial hemorrhages

,

disease progression

,

,

,

congenital heart defects

,

fontan procedure

drug interactions

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use